Night curfew in Pune on Tuesday. (Express photo by Ashish Kale)
Just two weeks after the Pune-based Serum Institute of India’s Covid-19 vaccine emergency use authorization (EUA) committee reviewing the Pune-based Serum Institute of India sought additional safety and efficacy data at the stage Late, the firm has submitted new data to the regulator, government sources. said.
Serum Institute India has submitted additional data. The regulator’s office, internally, will review these documents. Only then will they request that the Committee of Experts on the Matter (SEC) meet, ”sources told The Indian Express.
Significantly, the media has reported that the UK regulator is scheduled to “clean up” the Oxford-AstraZeneca vaccine, “possibly on December 28 and 29”. In India, the IBS requesting the US General Medicines Controller of India (DGCI) on December 10 was requested to submit safety data on Phase 2/3 clinical trials in India of its candidate vaccine called Covishield, developed by Oxford -AstraZeneca.
.
